News &amp; Updates

Fluvoxamine of little benefit in mild-to-moderate COVID-19

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

Fluvoxamine of little benefit in mild-to-moderate COVID-19

Higher red meat intake tied to higher risk of UC flare

02 Jan 2024 by

Higher red meat intake is linked to a higher risk of ulcerative colitis (UC) flare, according to an expert who presented findings from a recent study at AIBD 2023.

Higher red meat intake tied to higher risk of UC flare

Retinoblastoma treatment carries increased risk of neutropenia

Neutropenia following intra-arterial chemotherapy occurs more frequently than previously reported among children with retinoblastoma, with topotecan possibly linked to a risk increase, according to a study.

Retinoblastoma treatment carries increased risk of neutropenia

Statins protect against blood clots in people taking hormone therapy

30 Dec 2023 by

Statin therapy appears to mitigate the risk of venous thromboembolism associated with exogenous hormones, according to a study.

Statins protect against blood clots in people taking hormone therapy

Is premedication with pronase advisable to patients undergoing endoscopy?

Prior to upper gastrointestinal endoscopy, premedication with pronase helps achieve better mucosal visibility and reduce flushing frequency and volume, reports a study. However, this strategy does not appear to improve lesion detection rates.

Is premedication with pronase advisable to patients undergoing endoscopy?

Telitacicept shows promise in systemic lupus erythematosus

Telitacicept, a novel fusion protein that neutralizes signals of B lymphocyte stimulator and a proliferation-inducing ligand, is safe and helps improve the symptoms of systemic lupus erythematosus, as shown in a phase IIb study.

Telitacicept shows promise in systemic lupus erythematosus

30 Dec 2023

Brolucizumab noninferior to aflibercept for diabetic macular edema

In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.

Brolucizumab noninferior to aflibercept for diabetic macular edema

$Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma$

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023 by

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

What are the predictors of disability in pancreatitis patients?